Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Employee

Poster(s):

• (P-537) PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of life
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-545) Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1424) Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1879) Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT